Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.

A roundup of the first quarter's key oncology drug approvals and rejections.

The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.

Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.

Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.

Imetelstat appears headed for approval after its US adcom turns into a damp squib.

The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.

Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.